Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report
about
sameAs
Eradication therapy for peptic ulcer disease inHelicobacter pylori-positive peopleOptimum duration of regimens for Helicobacter pylori eradicationEradication therapy for peptic ulcer disease in Helicobacter pylori positive patientsLactobacillus johnsonii La1 attenuates Helicobacter pylori-associated gastritis and reduces levels of proinflammatory chemokines in C57BL/6 mice.Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus ReportH pylori antibiotic resistance: prevalence, importance, and advances in testingThe diagnostic value of endoscopy and Helicobacter pylori tests for peptic ulcer patients in late post-treatment settingSurvey of general practitioners' knowledge about Helicobacter pylori infectionSequential versus standard triple first-line therapy forHelicobacter pylorieradicationDiagnostic Methods of Helicobacter pylori Infection for Epidemiological Studies: Critical Importance of Indirect Test ValidationComparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysisTherapy of Helicobacter pylori: present medley and future prospectiveThe ferric uptake regulator of Helicobacter pylori: a critical player in the battle for iron and colonization of the stomachDiagnosis, treatment, and outcome in patients with bleeding peptic ulcers and Helicobacter pylori infectionsA review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication.Role of Helicobacter pylori eradication in aspirin or non-steroidal anti-inflammatory drug usersPeptic ulcer disease todayPrimer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risksCurrent approaches to prevent NSAID-induced gastropathy--COX selectivity and beyondManagement of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade PortuEvaluation and management of dyspepsia.Recent use of proton pump inhibitor-based triple therapies for the eradication of H pylori: a broad data review.Formulation and evaluation of stomach-specific amoxicillin-loaded carbopol-934P mucoadhesive microspheres for anti-Helicobacter pylori therapy.An in vivo model for gastric physiological and pathophysiological studies in the mouse.The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysisEfficacy of rifabutin-based triple therapy as second-line treatment to eradicate helicobacter pylori infectionShort-term triple therapy with azithromycin for Helicobacter pylori eradication: low cost, high compliance, but low efficacy'Rescue' therapies for the management of Helicobacter pylori infection.Treatment of Helicobacter pylori infection.Proof of an association between Helicobacter pylori and idiopathic thrombocytopenic purpura in Latin America.Hematologic manifestations of Helicobacter pylori infectionEffect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study.Pharmacokinetic interactions between ilaprazole and clarithromycin following ilaprazole, clarithromycin and amoxicillin triple therapy.Mucosal patterns of Helicobacter pylori-related gastritis without atrophy in the gastric corpus using standard endoscopyEvaluation of commercial immunoassays for detection of antibody against Helicobacter pylori in Thai dyspeptic patients.Genetic screening for familial gastric cancer.Cost-effectiveness of six strategies for Helicobacter pylori diagnosis and management in uninvestigated dyspepsia assuming a high resource intensity practice pattern.Omeprazole-based triple therapy with low-versus high-dose of clarithromycin plus amoxicillin for H pylori eradication in Iranian populationRecent developments in gastroenterology.Antimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days Moxifloxacin based therapy for the eradication: a randomized controlled trial.
P2860
Q24185883-6A5466D0-FAD7-4E32-A535-D68FAF996282Q24201841-CC87F847-2B52-4563-951A-BD88EF65585EQ24246267-52729C06-C4FD-49CF-A6D4-7F89B9377494Q24535026-81641CBA-0B7E-4D6C-98FC-3FE7A586C5D1Q24674636-BF429A5B-EF71-4B60-9EF2-7D4D97A596B0Q24685864-0E7F973E-EA68-4B50-9EAC-3B93291E9150Q24795125-B9D4ED76-9E60-4EE4-8F61-D20D220C1DFAQ24803936-10E990EF-520C-4659-AFED-74DD3F3ED529Q26471410-D5A8ADB2-4FB8-4F28-A4BA-6C5CB352B9EDQ26767158-80EDC1C4-B462-4F7B-980F-FAB09E8437AEQ26796367-433D982C-716F-4B27-AF55-FE5FBF8F93E9Q26823120-6B69C22C-6B36-4F51-99B4-50EE02BA5C01Q26823265-75BA3BBC-699D-4896-9A8C-3ABA27402D76Q27027870-1A4CDBEC-6F17-4EC6-A61F-46C64D1F4212Q27687842-53CBCC9D-F327-4F99-9910-C1BFBE867FBBQ28182449-159C9FF7-0B69-4EAC-90BB-952AD5874492Q28194844-231AE5DF-80FA-47B2-A985-5CDDFE24529EQ28200571-7244D8D0-B32A-4725-A3FD-4378707D364DQ28210656-DC508F31-47F2-4330-9373-27A9AA4B341CQ30426539-5ADF0531-2684-47F2-852C-D0C253209CEEQ30433839-74CD2530-1B7E-417E-8789-3BEA8137E473Q30781186-47B03BE2-770D-414D-8584-C3322A17ADF9Q30847388-38E13B9F-DD09-4902-B59B-1102FECDB792Q33215829-7B2F3DAD-36FD-469B-BF46-0D6D5103BF60Q33287535-3CCB0E9F-4C0A-46CD-B2AF-53793C1A0EFFQ33291670-B53C54E0-7775-4C83-A71F-8514EB2C9684Q33338688-38FA3B2D-9BBE-40C4-9F5A-DD8D22737C53Q33371187-93D474CF-7E7E-43C4-A56E-1D879E84B4E9Q33372344-E0F589E3-0F5B-4790-AE19-C86751615525Q33375206-1B63BEC3-7B21-4DF3-A43F-DC4DAEFF52E1Q33417972-C4BF55A3-D77A-479B-AFC7-28C0A0517494Q33426019-637C46DF-AD9C-4C40-8600-2B1A0B8779AAQ33571277-35023509-002E-4AD8-87FD-3A8B038423EBQ33612259-8A75CFC5-B2BF-408C-89C9-FD0680DD86A1Q33712002-D67C0615-04AE-4F0A-B34E-6D80152EDD0FQ33732282-C2BB07DF-1F41-4A17-A4D0-B41E83604916Q33777452-6B79AFAD-C9EF-4091-93B6-581DA7511A03Q33787766-75B8728E-92F2-4CAC-9C40-2AE6A761D963Q33813304-4BF1BC0B-089A-4124-A5CF-63EE2334143BQ33843119-5C933A61-0B6B-49CE-9BD5-167BF529E03B
P2860
Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Current concepts in the manage ...... tricht 2-2000 Consensus Report
@ast
Current concepts in the manage ...... tricht 2-2000 Consensus Report
@en
Current concepts in the manage ...... tricht 2-2000 Consensus Report
@nl
type
label
Current concepts in the manage ...... tricht 2-2000 Consensus Report
@ast
Current concepts in the manage ...... tricht 2-2000 Consensus Report
@en
Current concepts in the manage ...... tricht 2-2000 Consensus Report
@nl
prefLabel
Current concepts in the manage ...... tricht 2-2000 Consensus Report
@ast
Current concepts in the manage ...... tricht 2-2000 Consensus Report
@en
Current concepts in the manage ...... tricht 2-2000 Consensus Report
@nl
P2093
P2860
P3181
P1476
Current concepts in the manage ...... tricht 2-2000 Consensus Report
@en
P2093
C O'Morain
D Y Graham
P Malfertheiner
P2860
P304
P3181
P356
10.1046/J.1365-2036.2002.01169.X
P407
P577
2002-02-01T00:00:00Z